PMID- 29201720
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 2231-5047 (Print)
IS  - 2231-5128 (Electronic)
IS  - 2231-5047 (Linking)
VI  - 6
IP  - 1
DP  - 2016 Jan-Jun
TI  - Dynamic of Immune Response induced in Hepatitis B Surface Antigen-transgenic Mice 
      Immunized with a Novel Therapeutic Formulation.
PG  - 25-30
LID - 10.5005/jp-journals-10018-1161 [doi]
AB  - The development of therapeutic vaccines against chronic hepatitis B requires the 
      capacity of the formulation to subvert a tolerated immune response as well as the 
      evaluation of histopathological damage resulting from the treatment. In the 
      present study, the dynamicity of induced immune response to hepatitis B surface 
      antigen (HBsAg) was evaluated in transgenic mice that constitutively express the 
      HBsAg gene (HBsAg-tg mice). After immunization with a vaccine candidate 
      containing both surface (HBsAg) and core (HBcAg) antigens of hepatitis B virus 
      (HBV), the effect of vaccination on clearance of circulating HBsAg and the 
      potential histological alterations were examined. Transgenic (tg) and 
      non-transgenic (Ntg) mice were immunized by intranasal (IN) and subcutaneous (SC) 
      routes simultaneously. A control group received phosphate-buffered saline (PBS) 
      by IN route and aluminum by SC route. Positive responses, at both humoral and 
      cellular levels, were obtained after five immunizations in HBsAg-tg mice. Such 
      responses were delayed and of lower intensity in tg mice, compared to vaccinated 
      Ntg mice. Serum IgG response was characterized by a similar IgG subclass pattern. 
      Even when HBsAg-specific CD8(+) T cell responses were clearly detectable by 
      gamma-interferon ELISPOT assay, histopathological alterations were not detected 
      in any organ, including the liver and kidneys. Our study demonstrated, that it is 
      possible to subvert the immune tolerance against HBsAg in tg mice, opening a 
      window for new studies to optimize the schedule, dose, and formulation to improve 
      the immune response to the therapeutic vaccine candidate. These results can be 
      considered a safety proof to support clinical developments for the formulation 
      under study. HOW TO CITE THIS ARTICLE: Freyre FM, Blanco A, Trujillo H, Hernandez 
      D, Garcia D, Alba JS, Lopez M, Merino N, Lobaina Y, Aguilar JC. Dynamic of Immune 
      Response induced in Hepatitis B Surface Antigen-transgenic Mice Immunized with a 
      Novel Therapeutic Formulation. Euroasian J Hepato-Gastroenterol 2016;6(1):25-30.
FAU - Almeida, Freya M Freyre
AU  - Almeida FMF
AD  - Vaccine Division, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
FAU - Blanco, Aracelys
AU  - Blanco A
AD  - Animal Facilities, Center for Genetic Engineering and Biotechnology, Havana, 
      Cuba.
FAU - Trujillo, Heidy
AU  - Trujillo H
AD  - Vaccine Division, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
FAU - Hernandez, Dunia
AU  - Hernandez D
AD  - Vaccine Division, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
FAU - Garcia, Daymir
AU  - Garcia D
AD  - Vaccine Division, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
FAU - Alba, Jose S
AU  - Alba JS
AD  - Animal Facilities, Center for Genetic Engineering and Biotechnology, Havana, 
      Cuba.
FAU - Abad, Matilde Lopez
AU  - Abad ML
AD  - Technology Development Division, Center for Genetic Engineering and 
      Biotechnology, Havana, Cuba.
FAU - Merino, Nelson
AU  - Merino N
AD  - Food and Pharmacy Faculty, University of Havana, Havana, Cuba.
FAU - Lobaina, Yadira
AU  - Lobaina Y
AD  - Vaccine Division, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
FAU - Aguilar Rubido, Julio C
AU  - Aguilar Rubido JC
AD  - Vaccine Division, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
LA  - eng
PT  - Journal Article
DEP - 20160709
PL  - India
TA  - Euroasian J Hepatogastroenterol
JT  - Euroasian journal of hepato-gastroenterology
JID - 101577625
PMC - PMC5578554
OTO - NOTNLM
OT  - Chronic hepatitis B
OT  - HBV transgenic mice
OT  - HBcAg
OT  - HBsAg
OT  - Therapeutic vaccine.
COIS- Source of support: Center for Genetic Engineering and Biotechnology, Havana, 
      Cuba. Conflict of interest: None
EDAT- 2016/01/01 00:00
MHDA- 2016/01/01 00:01
PMCR- 2016/01/01
CRDT- 2017/12/05 06:00
PHST- 2015/11/12 00:00 [received]
PHST- 2015/12/29 00:00 [accepted]
PHST- 2017/12/05 06:00 [entrez]
PHST- 2016/01/01 00:00 [pubmed]
PHST- 2016/01/01 00:01 [medline]
PHST- 2016/01/01 00:00 [pmc-release]
AID - 10.5005/jp-journals-10018-1161 [doi]
PST - ppublish
SO  - Euroasian J Hepatogastroenterol. 2016 Jan-Jun;6(1):25-30. doi: 
      10.5005/jp-journals-10018-1161. Epub 2016 Jul 9.